Direct sample pathogen sequencing for diagnosis
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB45312 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Diagnosis of infectious diseases by sequencing
| PRJDB7111 | ENA
Project description:BACKGROUND: Classical Hodgkin lymphoma is dominated by the nonneoplastic microenvironment, while the neoplastic Hodgkin-Reed-Sternberg cells compose only a minority of cells in the lymphoma tissue. Both, the Hodgkin-Reed-Sternberg cells due to their expression of CD30 and PD-L1 and the microenvironment with abundant T-cells and expression of PD1 are specifically targeted by new treatment concepts. AIM: We aimed to understand the dynamics of therapeutic targets in patients treated with conventional chemotherapy. METHODS: We analyzed sequential biopsy specimens obtained at diagnosis and at relapse from the same patient for morphology, immunophenotype and microenvironmental components. RESULTS: The morphological subtype changed between primary and relapse biopsy in 20% of cases. The immunophenotype was stable with respect to CD30, CD3 and LMP1 but variable with respect to CD15 and CD20 expression. Gene expression revealed 8 up- and 20 down-regulated genes at relapse (p≤0.05) with a consistent logarithmic fold change direction in at least 75% of all cases. For PD1, we found discrepant results between gene expression analysis (decrease at relapse) and number of PD1 positive cells assessed by immunohistochemistry (unchanged at relapse). PD-L1 in the neoplastic cells appeared unchanged between primary diagnosis and relapse. CONCLUSION: The expression of the therapeutic targets CD30, PD1 and PD-L1 can reliably be assessed in tumor specimen at first diagnosis and are unchanged under conventional chemotherapy. We used digital multiplexed gene expression (DMGE) with FFPE derived RNA to analyze sequential biopsy specimens obtained at diagnosis and at relapse from the same patient for morphology, immunophenotype and microenvironmental components.
2019-06-24 | GSE125651 | GEO
Project description:Diagnosis by direct sequencing of pathogens
| PRJEB45350 | ENA
Project description:Metagenomic next-generation sequencing in diagnosis of infectious diseases
| PRJNA1066583 | ENA
Project description:Purpose: PCa is the second most commonly diagnosed malignancy in men. PCa Diagnosis are based on biopsy sampling that is an invasive, expensive procedure and does not accurately represent multifocal disease. It is desirable to have an easily accessible, minimally invasive way to accurately determine the molecular signature of patient’s tumor that can aid in diagnosis and risk stratification. Methods:we enrolled a total of 70 patients underwent 12-core transrectal ultrasound (TRUS) biopsy of which 48% had cancer in the diagnosis. The mean age at diagnosis was 67.15 (IR 55/75), the mean PSA (ng/ml) at diagnosis was 7.8 (IR 4.1/13.4) and the mean TRUS Volume (ml) was 53.5 (IR 29/86). The cancer biopsy presented 73.1% of positive core. Among all cancer patients, 57% showed a High grade of cancer status (Grade 3). Controls are patients with Benign Prostate Hyperplasia (BPH). MicroRNA-expression profiling (NGS analysis) was performed to identify tumor-related microRNAs (miRs) and determine their association with clinicopathological characteristics. Results: The expression of miRs -4732-3p, let7a, 26b-5p, 98-5p, 30c-5p and 21-5p may identified Prostate Cancer in plasma samples. Higher expression of mir-4732-3p is associated with a high grade tumor Conclusions: miRs signature discriminate Prostate cancer in plasma better to PSA values and is associated with high grade tumor status
2020-11-01 | GSE118038 | GEO
Project description:Endomyocardial biopsy (EMB) is the gold standard for diagnosis of several heart diseases, yet its use is limited by relatively low diagnostic yield and significant complication risks. To address this, we have developed an endovascular micro-biopsy (Micro-EMB) device with an outer diameter of 0.4 mm in order to minimize procedural risk, sampling trauma, and increase sampling specificity. We have performed RNA-seq on the resulting submilligram tissue as well as controls. The gene expression signatures were compared between Micro-EMBs and conventional EMB controls, as well as negative controls such as blood and skeletal muscle.
2020-05-21 | GSE124783 | GEO
Project description:The paper "Metabolomic Machine Learning Predictor for Diagnosis and Prognosis of Gastric Cancer" addresses the need for non-invasive diagnostic tools for gastric cancer (GC). Traditional methods like endoscopy are invasive and expensive. The authors conducted a targeted metabolomics analysis of 702 plasma samples to develop machine learning models for GC diagnosis and prognosis. The diagnostic model, using 10 metabolites, achieved a sensitivity of 0.905, outperforming conventional protein marker-based methods. The prognostic model effectively stratified patients into risk groups, surpassing traditional clinical models.
I have successfully reproduced the diagnosis model from the paper. This machine learning-based system differentiates GC patients from non-GC controls using metabolomics data from plasma samples analyzed by liquid chromatography-mass spectrometry (LC-MS). The model focuses on 10 metabolites, including succinate, uridine, lactate, and serotonin. Employing LASSO regression and a random forest classifier, the model achieved an AUROC of 0.967, with a sensitivity of 0.854 and specificity of 0.926. This model significantly outperforms traditional diagnostic methods and underscores the potential of integrating machine learning with metabolomics for early GC detection and treatment.
2024-07-23 | MODEL2407230001 | BioModels
Project description:Pathological examination of gastroscopy biopsy specimens will make false diagnosis for gastric cancer (GC) due to inaccurate sampling locations and/or insufficient sampling amount. We extracted a robust qualitative transcriptional signature, based on the within-sample relative expression orderings (REOs) of gene pairs, to discriminate both GC tissues and adjacent-normal tissues from non-GC gastritis and normal gastric tissues.The qualitative transcriptional signature can be robustly applied at the individual level to aid the diagnosis of early GC.
2018-07-10 | GSE116782 | GEO
Project description:This dataset contains peptide array information from 1516 patients from 12 different cancer types, 2 infectious diseases, and healthy controls using leave one out cross validation. This array is library 2 (GPL14921).
2013-12-15 | GSE52581 | GEO